Evidence map›Paper›PMID 38310390›Full record

ArticleCurrent medicinal chemistry2025

Dan Xiang, Huiyu Li, Jun Pan, Yitian Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Dan XiangDepartment of Medical Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, 210008, China.
Huiyu LiDepartment of Medical Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, 210008, China.
Jun PanDepartment of Medical Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, 210008, China.
Yitian ChenDepartment of Medical Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, 210008, China.
Nanjing General Hospital of Nanjing Military Command · CNSecond Affiliated Hospital of Nanjing Medical University · CN

Funding

National Natural Science Foundation of China (NSFC) 81972332, 81702442
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) cases with advanced or distal metastases experience a survival rate of less than 20%, with the lack of spectral therapeutic targets and prognostic markers posing a significant challenge for CRC treatment.

aimIn this report, we performed a comprehensive analysis of data on colorectal cancer (CRC) to elucidate the association among Solute Carrier Family 4 Member 4 (SLC4A4) and the abundance of immunological features and immune cell infiltration in CRC and to explore the impact of SLC4A4 on the CRC tumor microenvironment.

objectiveThe objective of this study was to systematically reveal the characteristics of the tumor microenvironment created by

methodsWe downloaded RNA sequencing files from the Cancer Genome Atlas (TCGA- COADREAD). The correlations of SLC4A4 with immune-related characteristics were analyzed. A Limma package was applied for selecting

resultsWe found that

conclusionOverall, upregulation of

Indexed as

Colorectal NeoplasmsInflammationSodium-Bicarbonate SymportersTumor MicroenvironmentHumansNomogramsPrognosisSLC4A4 protein, humanSodium-Bicarbonate SymportersColorectal cancerCRC therapy.immunogenicityimmunotherapyprognosisSLC4A4

Identifiers

PMID38310390
OpenAlexW4391522343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.